We analyzed the serum levels of S100A8, S100A9 and S100A12 from HBV-negative HCC patients, HBV-positive HCC patients and healthy controls by enzyme-linked immunosorbent assay (ELISA; Fig. 1a–c). This evidence concerns the gene S100A12 and hepatocellular carcinoma.